Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Prostate Cancer

The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of prostate cancer in Black patients.

Prostate Cancer in Black Individuals: How Can We Do Better?

The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of prostate cancer in Black patients.

Recognizing Bias and Health Care Disparities in Black Patients

The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast and prostate cancer in Black patients.

NCCN Guidelines® Insights - Prostate Cancer Early Detection, Version 1.2023
These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
Archived Monthly Oncology Tumor Boards: Management of Non-Metastatic Prostate Cancer
Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided. In addition, clinicians should be educated about the heterogeneity among risk groups, so that nuanced discussions with patients can inform decisions surrounding active surveillance.
Management of Patients with Non-Metastatic Prostate Cancer
Improved prognostication and risk stratification can help identify patients with localized prostate cancer who may derive greater or lesser absolute benefit from a given treatment, thus preventing over- and under-treatment. Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided.
Monthly Oncology Tumor Boards: Management of Non-Metastatic Prostate Cancer
Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided. In addition, clinicians should be educated about the heterogeneity among risk groups, so that nuanced discussions with patients can inform decisions surrounding active surveillance.
Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer
Relugolix has a unique place in therapy for the treatment of prostate cancer. As a first-in-class oral LHRH antagonist, relugolix provides many benefits for patients. However, it is critical to understand how to manage the potential toxicities, drug interactions and adherence issues when initiating and maintaining this new oral agent.
Clinical Scenario #4: Evolving Applications of PARP Inhibitors in Various Cancers
This activity will address the increasing use of PARP inhibitors in the management of patients with solid tumors, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.
NCCN Guidelines® Insights - Prostate Cancer, Version 1.2023
These NCCN Guidelines Insights summarizes much of the panel’s discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

Pages

Subscribe to RSS - Prostate Cancer